source
- Ionis shares tumble over $1 billion as Tryngolza sales forecast cut in halfIonis Pharmaceuticals saw its market value drop by more than $1 billion after it lowered its sales outlook for Tryngolza, a triglyceride‑lowering therapy. The company now expects $50 million in sa…
- FDA approves Bayer’s Sunharbo, first Factor XIa inhibitor to lower stroke recurrence riskThe Food and Drug Administration has approved Bayer's new medication intended to prevent another stroke in patients who have already experienced one. The drug, sold under the brand name Sunharbo,…